Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800.
SEER Cancer Statistics Review, 1975–2017, National Cancer Institute, National Cancer Institute. 2019. https://seer.cancer.gov/csr/1975_2017/ . Accessed 30 April 2020.
Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4(4):617–20.
Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13(71):287–97.
Mardani A, Gheytanchi E, Mousavie SH, Madjd Jabari Z, Shooshtarizadeh T. Clinical significance of cancer stem cell markers CD133 and CXCR4 in osteosarcomas. Asian Pac J Cancer Prev. 2020;21(1):67–73.
Gagliardi F, Narayanan A, Reni M, Franzin A, Mazza E, Boari N, et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia. 2014;62(7):1015–23.
Ye C, Zhang C, Huang H, Yang B, Xiao G, Kong D, et al. The natural compound myricetin effectively represses the malignant progression of prostate cancer by inhibiting PIM1 and disrupting the PIM1/CXCR4 Interaction. Cell Physiol Biochem. 2018;48(3):1230–44.
Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KHB, et al. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis. Front Pharmacol. 2018;9:1294–327.
Weixler B, Renetseder F, Facile I, Tosti N, Cremonesi E, Tampakis A, et al. Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer. Cell Oncol. 2017;40(6):609–19.
Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.
Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15(4):613–7.
Song JS, Jung JK, Park JC, Kim DK, Jang SJ. Association of CXCR4 expression with metastasis and survival among patients with non-small cell lung cancer. Korean J Pathol. 2008;42(6):358–64.
Wang M, Chen GY, Song HT, Hong X, Yang ZY, Sui GJ. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2011;2(3):517–22.
Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7–H1 and B7–H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6(5):3452–61.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, Fujiwara T, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 2008;33(1):113–9.
Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol. 2011;6(7):1169–78.
Al Zobair AA, Al Obeidy BF, Yang L, Yang C, Hui Y, Yu H, et al. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep. 2013;29(4):1524–32.
Li Y, Shen Y, Miao Y, Luan Y, Sun B, Qiu X. Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int J Clin Exp Pathol. 2014;7(7):3771–80.
Li XX, Li RJ, Zhao LJ, Liu NB, Wang P. Expression of molecular factors correlated with metastasis in small cell lung cancer and their significance. Int J Clin Exp Pathol. 2015;8(11):14676–84.
Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, Baum RP, et al. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget. 2015;6(5):3346–58.
Zuo J, Wen M, Li S, Lv X, Wang L, Ai X, et al. Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9. Oncol Lett. 2017;14(6):7513–21.
He L, Deng H, Liu S, Chen J, Li B, Wang C, et al. Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4. Cancer Commun. 2018;38(1):53–66.
Katsura M, Shoji F, Okamoto T, Shimamatsu S, Hirai F, Toyokawa G, et al. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients. Cancer Sci. 2018;109(1):154–65.
Zhu Q, Luo R, Gu J, Hou Y, Chen Z, Xu F, et al. High CXCR4 expression predicts a poor prognosis in resected lung adenosquamous carcinoma. J Cancer. 2020;11(4):810–8.
Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009;137(3):615–21.
Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res. 2005;11(23):8273–80.
Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, et al. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol. 2008;39(12):1751–5.
Chen G, Wang Z, Liu XY, Liu FY. High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J Surg. 2011;35(1):56–61.
Zhou Z, Chen ZW, Yang XH, Shen L, Ai XH, Lu S, et al. Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer. J Exp Clin Cancer Res. 2012;31:34–9.
Wang L, Wang Z, Liu X, Liu F. High-level C-X-C chemokine receptor type 4 expression correlates with brain-specific metastasis following complete resection of non-small cell lung cancer. Oncol Lett. 2014;7(6):1871–6.
Bi MM, Shang B, Wang Z, Chen G. Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer. Thorac Cancer. 2017;8(6):634–41.
Liu Y, Wu B, Geng H, Xu M, Zhong H. Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma. Oncol Lett. 2015;10(3):1315–22.
Cong Z, Wu H, Guo Z, Qin T, Xu Y, Jing H, et al. High expression of C-X-C chemokine receptor 4 and Notch1 is predictive of lymphovascular invasion and poor prognosis in lung adenocarcinoma. Tumour Biol. 2017;39(6):1010428317708698.
Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003;105(2):186–9.
Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol. 2006;177(10):6983–90.
Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–90.
Franco R, Pirozzi G, Scala S, Cantile M, Scognamiglio G, Camerlingo R, et al. CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg. 2012;41(2):368–75.
Zhou Y, Cao HB, Li WJ, Zhao L. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy. Chin J Nat Med. 2018;16(11):801–10.
Portella L, Bello A, Scala S. CXCL12 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1302:51–70.
Sterlacci W, Saker S, Huber B, Fiegl M, Tzankov A. Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. Virchows Arch. 2016;468(4):463–71.
Economidou F, Antoniou K, Soufla G, Lasithiotaki I, Karagiannis K, Lymbouridou R, et al. Role of VEGF-stromal cell-derived factor-1alpha/CXCL12 axis in pleural effusion of lung cancer. J Recept Signal Transduct Res. 2010;30(3):154–60.
Bertolini G, Cancila V, Tripodo C, Sozzi G, Lo Russo G, Fortunato O, et al. Cisplatin sustains lung cancer metastasis through the systemic activation of SDF-1/CXCR4 axis. J Thorac Oncol. 2019;14(10):S303-S.
Mortezaee K. CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis. Life sci. 2020;249:117534–42.
Bai L, Guo C, Wu H, Kaye AD, Jin C, Deng L, et al. The prognostic value of C-X-C chemokine receptor 4 in non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med. 2017;10(2):2285–95.
Liu K, Bao C, Yao N, Miao C, Varlotto J, Sun Q, et al. Expression of CXCR4 and non-small cell lung cancer prognosis: a meta-analysis. Int J Clin Exp Med. 2015;8(5):7435–45.
Stumpf C, Kaemmerer D, Neubauer E, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. J Cancer Res Clin Oncol. 2018;144(10):1921–32.
Shim B, Jin M, Moon J, Park I, Ryu H. High cytoplasmic CXCR4 expression predicts prolonged survival in triple-negative breast cancer patients treated with adjuvant chemotherapy. J Pathol Transl Med. 2018;52(6):369–77.
Zeelenberg I, Ruuls-Van Stalle L, Roos E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. J Clin Invest. 2001;108(2):269–77.
Saba N, Wang Y, Fu H, Koenig L, Khuri F, Shin D, et al. Association of cytoplasmic CXCR4 with loss of epithelial marker and activation of ERK1/2 and AKT signaling pathways in non-small-cell lung cancer. Clin Lung Cancer. 2017;18(3):e203–10.
Wei Y, Wang X, Yang S, Zhou S, Zhang H. The expression and significance of tumor associated macrophages and CXCR4 in non-small cell lung cancer. J BUON. 2018;23(2):398–402.
Zeng Y, Wang X, Yin B, Xia G, Shen Z, Gu W, et al. Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism. J Thorac Dis. 2017;9(12):4947–59.
Jupiter D. Causal diagrams and multivariate analysis III: confound it! J Foot Ankle Surg. 2015;54(1):145–7.
Paratore S, Banna GL, D’Arrigo M, Saita S, Iemmolo R, Lucenti L, et al. CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. Cancer Biomark. 2011;10(2):79–89.
Liao T, Chen W, Sun J, Zhang Y, Hu X, Yang S, et al. CXCR4 accelerates osteoclastogenesis induced by non-small cell lung carcinoma cells through self-potentiation and VCAM1 secretion. Cell Physiol Biochem. 2018;50(3):1084–99.
Ben-Baruch A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. Cell Adh Migr. 2009;3(4):328–33.
Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 2010;10:376–84.
Begley LA, Kasina S, Shah RB, Macoska JA. Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent. Am J Clin Exp Urol. 2015;3(2):91–9.
Rahimi M, George J, Tang C. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int J Cancer. 2010;126(8):1850–60.
Wu J, Liu Y, Ma Y, Wang R, Ji X, Zhang Y, et al. Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice. Int J Clin Exp Pathol. 2020;13(2):132–41.
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37(2):1253–62.
Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3(1):34–9.
Lee BC, Lee TH, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res. 2004;2(6):327–38.
He W, Yang T, Gong XH, Qin RZ, Zhang XD, Liu WD. Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells. Oncol Lett. 2018;16(3):3976–82.
Xie S, Tu Z, Xiong J, Kang G, Zhao L, Hu W, et al. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Oncol Rep. 2017;37(2):921–8.
Zhu Q, Zhang Z, Lu C, Xu F, Mao W, Zhang K, et al. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation. Clin Transl Oncol. 2020;22(8):1355–63.
D’Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Canc Res. 2019;38(1):432–44.
Tahirovic YA, Pelly S, Jecs E, Miller EJ, Sharma SK, Liotta DC, et al. Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. Expert Opin Ther Pat. 2020;30(2):87–101.